| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 240.0 | 223.9 | 193.0 |
| Other income | 4.2 | 4.3 | 4.7 |
| Total income | 244.2 | 228.3 | 197.7 |
| Profit before exceptional items & tax | 67.6 | 63.9 | 50.2 |
| Profit before tax | 68.3 | 64.4 | 50.5 |
| Net profit | 51.3 | 48.7 | 38.3 |
| Operating margin | 28.0% | 28.2% | 25.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +33.90% |
|---|---|
| Net profit, quarter on quarter | +5.30% |
| Revenue, year on year | +24.40% |
| Operating profit, year on year | +40.20% |
| Operating profit, quarter on quarter | +6.10% |
BSE results filing, NSE: THYROCARE. Figures extracted from the filing.
Thyrocare Technologies Ltd: key numbers
- Share price
- ₹566.85
- Market cap
- ₹9,022 Cr
- Revenue (annual)
- ₹829.0 Cr
- Net profit (annual)
- ₹163.0 Cr
- P/E (TTM)
- 51.2×Sector 57.8×
- Promoter holding
- 60.92%+0.00% QoQ
- FII holding
- 5.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Thyrocare Technologies Ltd
All →Thyrocare Technologies Employee Stock Options
Thyrocare Technologies Limited has granted 1,92,000 employee stock options to eligible employees under the company's approved stock option scheme.
Thyrocare Technologies Merger & Restructuring Worth ₹141.4 Cr
Thyrocare's board approved sale of 100% in Nueclear Healthcare to Trovera for ~₹141.40 Crore. The move exits radiology to refocus on core pathology business.
- Value
- ₹141.4 Cr
- Execution
- On or before November 30, 2026
Thyrocare Technologies Share Pledge
API Holdings, successor to promoter Docon, released a full pledge over 7.95 crore Thyrocare shares after NCD redemption. No Docon shares remain encumbered.
Thyrocare Technologies Acquisition
API Holdings Limited reported an exempt acquisition of 8.12 crore shares (51.02%) of Thyrocare Technologies Limited, pursuant to the amalgamation of Docon Technologies Private Limited.
Thyrocare Technologies Promoter Buying (Off-Market)
API Holdings acquired 8,12,00,000 shares (51.02%) of Thyrocare Technologies via a NCLT-approved scheme of amalgamation. The transfer resulted from the merger of Docon Technologies into API Holdings.
- Promoter stake change
- +51.02%
Thyrocare Technologies Earnings Call Transcript: Key Takeaways
Thyrocare Q1 FY27: Consolidated revenue grew 24.3% YoY to INR 240 Cr, EBITDA margin expanded to 32.2%. Strategy shifts toward specialty diagnostics.
- Call
- Guides 18% growth